Trial Profile

Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RE 02 (Primary) ; Mannitol
Indications Unspecified
Focus Adverse reactions; Pharmacokinetics
Sponsors Reconnect Labs

Most Recent Events

25 Nov 2024 According to ClinicalTrials.gov: US National Institutes of Health, this trial was terminated as the trial was closed due to futility
25 Nov 2024 Status changed from recruiting to discontinued.
20 Nov 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com